Dartmouth Cancer Center Names Dr. Roy Herbst as its New Director
Roy Herbst, MD, PhD, has been appointed the sixth director of the Dartmouth Cancer Center (DCC), according to a March 2026 press release. Dr. Herbst most recently served as deputy director and chief of medical oncology and hematology at Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut, where he led major research programs and expanded access to innovative therapies.
An internationally recognized expert, Dr. Herbst has contributed to the implementation of innovative clinical trial designs, the development of the Lung Master Protocol (Lung-MAP), and the approval of multiple targeted therapies.
Dr. Herbst has received several prestigious awards, including the IASLC Paul Bunn Scientific Award and the American Association for Cancer Research (AACR) Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy. He is also a dedicated educator, mentor, and advocate for tobacco control and regulation. Dr. Herbst’s tenure at DCC will begin on July 13, 2026.
Temple Health Appoints Dr. Robert A. Winn as Director of the Fox Chase Cancer Center
In March 2026, Temple Health announced the appointment of Robert A. Winn, MD, as the new director of the Fox Chase Cancer Center. Dr. Winn will begin his tenure at Temple Health this summer, where he will continue advancing Fox Chase’s dedication to shaping thoracic oncology by focusing on fostering collaboration and promoting research progress.
Previously, Dr. Winn served as the Director of the Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, where he holds the Lipman Chair in Oncology. During his time at VCU Massey Cancer Center, Dr. Winn played a key role in expanding research funding, bolstering team science, and increasing clinical participation. Additionally, he helped drive an institutional transformation that resulted in the center achieving National Cancer Institute Comprehensive Cancer Center designation in 2023.
Dr. Winn’s distinguished career as a nationally recognized physician and researcher includes a focus on community impact and advancing research aimed at addressing cancer disparities. He is highly regarded for his commitment to community engagement, having founded the Robert A. Winn Diversity in Clinical Trials Award Program and pioneered a “community-to-bench” model that integrates community perspectives into scientific research.
City of Hope Appoints Dr. Christine M. Lovly to Lead National Oncology Program
Christine M. Lovly, MD, PhD, FASCO, is the new division chief of Thoracic Medical Oncology, as well as a professor in the Department of Medical Oncology & Therapeutics Research, at City of Hope National Medical Center. Dr. Lovly will also hold the Dr. Norman and Melinda Payson Professorship in Medical Oncology.
Dr. Lovly is a leading expert in targeted therapy response and resistance, with nearly two decades of experience in clinical care, academic leadership, and translational research. Her distinguished portfolio includes significant research projects focused on biomarkers, residual disease, and drug development.
Dr. Lovly joins the City of Hope after serving as a faculty member at Vanderbilt University, where she held a joint appointment at the Veterans Affairs Medical Center. She has received several accolades, including the LUNGevity Foundation’s Face of Hope Award and the 2025 William J. Darby Award for translational research that has changed the practice of medicine worldwide.
